deals, Biotech, Stocks

Dynogen Goes Public Via Reverse Merger

Rebecca Zacks 2/6/08

Waltham, MA-based Dynogen announced today that it will go public in a reverse merger with a subsidiary of California’s Apex Bioventures. The subsidiary, Apex Bioventures Acquisition (AMEX: PEX) was set up for the purpose of acquiring a private firm. The Boston Business Journal has a nice run-down of the details of the somewhat unusual deal, under which Dynogen shareholders will receive some $98 million in Apex Bioventures stock.